文献速递心脏核医学

心脏淀粉样变性的放射性核素显像:现状更新与未来展望

Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects.
PubMed 文献 · Semin Nucl Med · 2024-07-03

心脏淀粉样变性由蛋白质错误折叠沉积于心肌细胞外间隙所致,主要分为转甲状腺素蛋白型(ATTR)和轻链型(AL),早期诊断可及时治疗改善预后。骨亲和性示踪剂SPECT已进入ATTR-CA标准诊断路径并使诊断非侵入化,淀粉样蛋白结合示踪剂PET可检测各类型CA但尚未获批临床使用。两种技术均在早期诊断、危险分层和疗效监测方面展现潜力,但仍需更多研究。

要点

  • 骨亲和性示踪剂SPECT已进入CA标准诊断路径,使ATTR-CA诊断非侵入化并促成更早期诊断。
  • 淀粉样蛋白结合示踪剂PET对淀粉样沉积真正特异,可检测ATTR-CA、AL-CA及罕见遗传型,但尚未获批临床用于CA。
  • SPECT和PET可预测不良结局,但如何与常规预后分期评分联合使用仍需更多证据。

核心结论

  • 放射性核素显像在CA的诊断、预后和随访方面有潜力进一步改变疾病格局,并可能大幅助力评估改善CA患者生活的新疗法。
  • 淀粉样蛋白结合示踪剂PET已积累大量证据,但尚未获批用于CA临床;需进一步研究以完善采集方案并在更广泛人群中验证结果。
  • SPECT和PET均可预测不良结局,但需更多证据确定如何将其与常规预后分期评分联合使用。
  • 关于治疗后随访显像的研究提示SPECT和PET能捕捉CA的心肌变化,但需更多数据才能有意义地解读这些变化。

研究设计与样本

  • 本文为综述,总结放射性核素显像(骨亲和性示踪剂SPECT与淀粉样蛋白结合示踪剂PET)在心脏淀粉样变性中的应用现状与未来方向。

主要发现

  • SPECT已进入CA标准诊断路径,使ATTR-CA诊断非侵入化并促成更早期诊断,还改变了ATTR-CA的流行病学认识,显示该病远比既往认为的常见,且在射血分数保留的心力衰竭(HFpEF)和主动脉瓣狭窄中起重要作用,尤其是老年患者。
  • 与骨亲和性SPECT示踪剂不同,PET示踪剂专为结合淀粉样纤维而设计,PET是唯一对淀粉样沉积真正特异且对各淀粉样类型高度敏感的影像方法,不仅能检测ATTR-CA,还能检测AL-CA和罕见遗传型。
  • SPECT和PET在心肌摄取定量方面的进展产生了更精细、可重复的结果,为更早期诊断、危险分层和治疗反应监测的进步铺路。
  • 令人鼓舞的发现显示,当其他诊断方法为阴性时,SPECT和PET对早期CA仍敏感。
  • 治疗后随访显像研究提示SPECT和PET能捕捉CA的心肌变化。

临床怎么用

  • SPECT已进入CA的标准诊断路径。
  • 淀粉样蛋白结合示踪剂PET尚未获批用于CA临床。
  • 原文未据此给出其他推荐。

局限性

  • 淀粉样蛋白结合示踪剂PET尚未获批用于CA临床,需进一步研究以完善采集方案并在更广泛人群中验证结果。
  • 需更多证据确定如何将SPECT和PET与常规预后分期评分联合使用。
  • 治疗后随访显像需更多数据才能有意义地解读SPECT和PET捕捉到的心肌变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac amyloidosis (CA) is caused by the misfolding, accumulation and aggregation of proteins into large fibrils in the extracellular compartment of the myocardium, leading to restrictive cardiomyopathy, heart failure and death. The major forms are transthyretin (ATTR) CA and light-chain (AL) CA, based on the respective precursor protein. Each of them requires early diagnosis for a timely treatment initiation that will improve patient outcomes. For this, radionuclide imaging is essentially used as single-photon emission computed tomography (SPECT) with bone-avid radiotracers or as positron emission tomography (PET) with amyloid-binding radiotracers. Both offer unprecedented specificity for the diagnostic of CA. SPECT has even revolutionized the diagnosis of ATTR-CA by making it non-invasive. Indeed, SPECT has now entered the standard diagnostic pathway to CA and has led to earlier diagnosis of the disease. SPECT also modified the epidemiology of ATTR-CA, highlighting that the disease is much more frequent than previously believed, and showing that ATTR-CA plays a substantial role in HFpEF and aortic stenosis, particularly among elderly patients. In parallel, amyloid-binding radiotracers for PET have accumulated a substantial amount of evidence, but are not approved for clinical use in CA yet. Further studies are needed to refine acquisition protocols and validate results in broader populations. Unlike bone-avid SPECT radiotracers, PET radiotracers have been specifically created to bind to amyloid fibrils. Thus, PET is the only imaging method that is truly specific for amyloid deposits and very sensitive to any amyloid type. Indeed, PET can not only detect ATTR-CA, but also AL-CA and rare hereditary forms. For both SPECT and PET, advances in quantitation of myocardial uptake have generated more granular and reproducible findings, paving the way for progress in earlier diagnosis, risk stratification and therapeutic response monitoring. Encouraging findings have shown that SPECT and PET are sensitive to early CA when other diagnostic methods are negative. Both radionuclide imaging techniques can predict adverse outcomes, but more evidence is needed to determine how to use them in conjunction with usual prognostic staging scores. Studies on follow-up imaging after therapy suggested that SPECT and PET can capture myocardial changes in CA, but again, more data are needed to meaningfully interpret such changes. Based on all these promising results, radionuclide imaging has the potential to further impact the landscape of CA in diagnosis, prognosis and follow-up, but also to substantially contribute to the assessment of novel therapies that will improve the lives of patients with CA.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Clerc OF, Vijayakumar S, Dorbala S, et al. Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects. Semin Nucl Med. 2024. PMID: 38960850. doi:10.1053/j.semnuclmed.2024.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。